Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Group ACYW135 meningococcal polysaccharide conjugate vaccine (Zhifei Lvzhu)
- Development stage
- Unknown
- Lead developer
- Zhifei Biological
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Group ACYW135 meningococcal polysaccharide conjugate vaccine is a quadrivalent vaccine developed by Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd., a subsidiary of Chongqing Zhifei Biological Products. It is designed to provide active immunization against invasive meningococcal disease caused by *Neisseria meningitidis* serogroups A, C, Y, and W135. The vaccine is composed of purified capsular polysaccharides from each of the four serogroups, each covalently conjugated to a tetanus toxoid (TT) carrier protein. This conjugation technology converts the T-cell independent polysaccharide antigens into T-cell dependent antigens, which significantly enhances immunogenicity and induces long-lasting immunological memory, particularly in infants and young children. The vaccine is administered via intramuscular injection and has completed Phase 3 clinical trials in China, with marketing authorization applications submitted to the National Medical Products Administration (NMPA).
- Brand names
- Menwayc
- Other names
- ACYW135 meningococcal polysaccharide conjugate vaccineACYW-135 meningococcal polysaccharide conjugate vaccineACYW 135 meningococcal polysaccharide conjugate vaccineGroup ACYW135 meningococcal polysaccharide tetanus toxoid conjugate vaccineQuadrivalent meningococcal polysaccharide conjugate vaccineACYW-TT
02
Targets
Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)
Beyond the preview
Go deeper on Group ACYW135 meningococcal polysaccharide conjugate vaccine (Zhifei Lvzhu).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Group ACYW135 meningococcal polysaccharide conjugate vaccine (Zhifei Lvzhu).